The contributions of dipeptidyl peptidase IV to inflammation in heart failure
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2016
Editora
AMER PHYSIOLOGICAL SOC
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
ANTONIO, Ednei Luiz
SANTOS, Leonardo dos
TUCCI, Paulo Jose Ferreira
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, v.310, n.11, p.H1760-H1772, 2016
Resumo
Circulating dipeptidyl peptidase IV (DPPIV) activity correlates with cardiac dysfunction in humans and experimental heart failure (HF) models. Similarly, inflammatory markers are associated with poorer outcomes in HF patients. However, the contributions of DPPIV to inflammation in HF remain elusive. Therefore, this study aimed to investigate whether the cardioprotective effects of DPPIV inhibition after myocardial injury are accompanied by reduced cardiac inflammation, whether circulating DPPIV activity correlates with the levels of systemic inflammatory markers in HF patients, and whether leukocytes and/or splenocytes may be one of the sources of circulating DPPIV in HF. Experimental HF was induced in male Wistar rats by left ventricular myocardial injury after radiofrequency catheter ablation. The rats were divided into three groups: sham, HF, and HF + DPPIV inhibitor (sitagliptin). Six weeks after surgery, cardiac function, perfusion and inflammatory status were evaluated. Sitagliptin treatment improved cardiac function and perfusion, reduced macrophage infiltration, and diminished the levels of inflammatory biomarkers including TNF-alpha, IL-1 beta, and CCL2. In HF patients, serum DPPIV activity correlated with CCL2, suggesting that leukocytes may be the source of circulating DPPIV in HF. Unexpectedly, DPPIV release was higher in splenocytes from HF rats and similar in HF circulating mononuclear cells compared with those from sham, suggesting an organ-specific modulation of DPPIV in HF. Collectively, our data provide new evidence that the cardioprotective effects of DPPIV inhibition in HF may be due to suppression of inflammatory cytokines. Moreover, they suggest that a vicious circle between DPPIV and inflammation may contribute to HF development and progression.
Palavras-chave
cardiac dysfunction, proinflammatory cytokines, sitagliptin, spleen, glucagon-like peptide-1
Referências
- Angeli FS, 2014, FRONT HORM RES, V43, P144, DOI 10.1159/000360598
- Aroor AR, 2014, AM J PHYSIOL-HEART C, V307, pH477, DOI 10.1152/ajpheart.00209.2014
- Nathan DM, 2007, NEW ENGL J MED, V356, P437, DOI 10.1056/NEJMp068294
- Ma KK, 2004, J MOL CELL CARDIOL, V36, P505, DOI 10.1016/j.yjmcc.2004.01.001
- Takahashi A, 2013, AM J PHYSIOL-HEART C, V304, pH1361, DOI 10.1152/ajpheart.00454.2012
- Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008
- Lugari R, 2004, HORM METAB RES, V36, P111, DOI 10.1055/s-2004-814222
- Frangogiannis NG, 2014, NAT REV CARDIOL, V11, P255, DOI 10.1038/nrcardio.2014.28
- Rizzo MR, 2012, DIABETES CARE, V35, P2076, DOI 10.2337/dc12-0199
- Ismahil MA, 2014, CIRC RES, V114, P266, DOI 10.1161/CIRCRESAHA.113.301720
- Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354
- dos Santos L, 2013, CIRC-HEART FAIL, V6, P1029, DOI 10.1161/CIRCHEARTFAILURE.112.000057
- Aukrust P, 1998, CIRCULATION, V97, P1136
- Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
- TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7
- Kemp CD, 2012, CARDIOVASC PATHOL, V21, P365, DOI 10.1016/j.carpath.2011.11.007
- Boerrigter G, 2007, AM J PHYSIOL-REG I, V292, pR897, DOI 10.1152/ajpregu.00569.2006
- Satoh-Asahara N, 2013, METABOLISM, V62, P347, DOI 10.1016/j.metabol.2012.09.004
- Frangogiannis NG, 2007, J AM COLL CARDIOL, V50, P2125, DOI 10.1016/j.jacc.2007.08.027
- Bozkurt B, 2010, HEART FAIL REV, V15, P331, DOI 10.1007/s10741-009-9140-3
- Shiraishi D, 2012, BIOCHEM BIOPH RES CO, V425, P304, DOI 10.1016/j.bbrc.2012.07.086
- Nistala R, 2014, ENDOCRINOLOGY, V155, P2266, DOI 10.1210/en.2013-1920
- Pacheco BPM, 2011, J HYPERTENS, V29, P520, DOI 10.1097/HJH.0b013e328341939d
- Glezeva N, 2013, J CARDIOVASC TRANSL, V6, P545, DOI 10.1007/s12265-013-9456-1
- Ban K, 2008, CIRCULATION, V117, P2340, DOI 10.1161/CIRCULATIONAHA.107.739938
- Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352
- Inoue BH, 2012, AM J PHYSIOL-REG I, V302, pR166, DOI 10.1152/ajpregu.00127.2011
- Salles TA, 2015, INT J MOL SCI, V16, P4226, DOI 10.3390/ijms16024226
- Antonio EL, 2009, J CARD FAIL, V15, P540, DOI 10.1016/j.cardfail.2009.01.007
- Lourenco P, 2013, J CARDIOVASC PHARM, V62, P138, DOI 10.1097/FJC.0b013e3182949673
- Takahashi M, 2010, CIRC J, V74, P418, DOI 10.1253/circj.CJ-09-1021
- Saleh MA, 2015, J CLIN INVEST, V125, P1189, DOI 10.1172/JCI76327
- Zannad F, 2015, LANCET, V385, P2067, DOI 10.1016/S0140-6736(14)62225-X
- MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601
- Sauve M, 2010, DIABETES, V59, P1063, DOI 10.2337/db09-0955
- Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
- Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
- Kroller-Schon S, 2012, CARDIOVASC RES, V96, P140, DOI 10.1093/cvr/cvs246
- LOWRY OH, 1951, J BIOL CHEM, V193, P265
- Doehner W, 2014, J AM COLL CARDIOL, V64, P1388, DOI 10.1016/j.jacc.2014.04.083
- Matsubara J, 2013, CIRC J, V77, P1337, DOI 10.1253/circj.CJ-12-1168
- Zaruba MM, 2009, CELL STEM CELL, V4, P313, DOI 10.1016/j.stem.2009.02.013
- Shigeta T, 2012, CIRCULATION, V126, P1838, DOI 10.1161/CIRCULATIONAHA.112.096479
- Leuschner F, 2012, J EXP MED, V209, P123, DOI 10.1084/jem.20111009
- Mason RP, 2012, J CARDIOVASC PHARM, V60, P467, DOI 10.1097/FJC.0b013e31826be204
- Mann DL, 2015, CIRC RES, V116, P1254, DOI 10.1161/CIRCRESAHA.116.302317
- Richardson P, 1996, CIRCULATION, V93, P841
- Wu L, 2014, P NATL ACAD SCI USA, V111, pE4638, DOI 10.1073/pnas.1324052111
- White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889
- Aoyama M, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002081
- Avogaro A, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0483-3
- Davies John Q, 2005, Methods Mol Biol, V290, P91
- HOPSUHAV.VK, 1966, HISTOCHEMISTRY, V7, P197, DOI 10.1007/BF00577838
- Scirica BM, 2014, CIRCULATION, V130, P1579, DOI 10.1161/CIRCULATIONAHA.114.010389
- Shah Z, 2011, CIRCULATION, V124, P2339, DOI 10.1161/CIRCULATIONAHA.111.041418
- van der Laan AM, 2014, EUR HEART J, V35, P376, DOI 10.1093/eurheartj/eht331
- Waumans Y, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00387
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Carregar mais Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13